MedTrace Logo

Allogeneic UCB-derived CAR-T for SLE

NCT07274059 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-12-10

No results posted yet for this study

Summary

The purpose of this clinical trial is to learn if allogeneic, umbilical cord blood-derived chimeric antigen receptor T-cell (UCAR-T) targeting CD19 and BCMA works to treat refractory SLE in adults. It will also learn about the safety and efficacy of the UCAR-T cell product.

Conditions

  • SLE - Systemic Lupus Erythematosus

Interventions

DRUG

allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA

intravenous injection of allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA

Sponsors & Collaborators

  • The General Hospital of Western Theater Command

    collaborator OTHER

  • Yancheng Third People's Hospital

    collaborator UNKNOWN

  • Chengdu Ucello Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Tao Wang, M.D. · The General Hospital of Western Theater Command

  • Mei Dong Jiang, M.D. · Yancheng Third People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-26
Primary Completion
2035-12-31
Completion
2037-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07274059 on ClinicalTrials.gov